We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Research · October 29, 2019

First-Line Sunitinib in Metastatic RCC: Costs and Effects

Anticancer Research


Additional Info

Anticancer Research
Sunitinib First-Line Treatment in Metastatic Renal Cell Carcinoma: Costs and Effects
Anticancer Res. 2019 Oct 01;39(10)5559-5564, RL Vuorinen, N Paunu, T Turpeenniemi-Hujanen, T Reunamo, A Jekunen, V Kataja, H Sintonen, T Purmonen, PL Kellokumpu-Lehtinen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.